263: Biogen's messy board, Laronde's data problem, & the downside of a boom
Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as \u201cModerna 2.0,\u201d ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen's boardroom scandal has roiled a company that was supposed to be entering a new era.